Cassava Sciences is laying off 10 employees —a third of its workforce—as the biotech seeks to conserve cash in the wake of ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.11% ...

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late ...

Cassava Science provided a business update. In November 2024, Cassava reported that the topline results from the Phase 3 RETHINK-ALZ study ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn ...

Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $2.36 which represents a decrease of $-0.04 or -1.67% from the prior close of $2.4. The stock opened at $2.36 and touched a low of $2 ...

Notable profits for the buyer who lifted the $0.25 offer for 9,851 Cassava Sciences (SAVA) Feb-25 3 calls yesterday at 10:51ET when underlying shares were trading at $2.65. Shares closed at $2.75 ...

Cassava Sciences has a 12-month low of $2.23 and a 12-month high of $42.20. The business’s fifty day simple moving average is $12.39 and its 200-day simple moving average is $19.58. Get Cassava ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

SAVA Stockholders Have Opportunity to Lead Cassava Sciences, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment inclu ...